Module 4.2.1 — Pharmacology Study Reports — GLPI-103
📚 Part of the GLPI-103 Regulatory Dossier — Reader's Guide. This article shows the live document; edits to the source appear here automatically.
This is a mock / simulation document, made for a portfolio and for learning. The drug (GLPI-103), the sponsor, the people, and the data are all fictional. It is not a real regulatory submission and has no clinical, legal, or regulatory standing. What is real is the shape of the thing — the document structure, the standards it follows, and the analysis methods; the content inside is illustrative.
What it is. Module 4.2.1 — the pharmacology study reports: primary (does it work), secondary, and safety pharmacology.
Why it exists. Before humans, animal pharmacology shows the drug engages its target (here GLP-1 and APJ receptors) and screens core organ systems (cardiovascular, respiratory, CNS) for hazards under ICH S7.
How it is produced here. No real animal studies were run for this portfolio, so this is deep-knowledge mock: the study designs, endpoints, and conclusions are realistic domain content standing in for real laboratory data.
Format & governing standard. ICH M4S; M3(R2); S7A/S7B; GLP (safety pharmacology core battery)
Module 4.2.1 — Pharmacology Study Reports — GLPI-103
| Field | Value |
|---|---|
| Document ID | M4-2.1 |
| Version | 2.0 (expanded) |
| Compound | GLPI-103 (GLP-1/APJ dual agonist) |
| Standard | ICH M4S; M3(R2); S7A/S7B; GLP (safety pharmacology core battery) |
| Confidentiality | Confidential |
[MOCK — deep-knowledge assumption]Nonclinical pharmacology study reports; all data illustrative but technically representative. Interpretive overview in M2.4; tabulated summary in M2.6.
Change History
| Version | Date | Author | Summary |
|---|---|---|---|
| 1.0 | 2026-06-29 | Nonclinical | Initial study reports |
| 2.0 | 2026-06-30 | Nonclinical | Expanded — in-vitro potency/selectivity, quantitative in-vivo efficacy, mechanistic (APJ) cardiac/vascular readouts, safety-pharmacology margins |
4.2.1.1 Primary Pharmacodynamics
Report PD-IVT-01 — In-vitro receptor pharmacology (non-GLP)
Objective: Characterise potency, efficacy, and selectivity at the two intended targets.
| Assay | Readout | GLPI-103 [MOCK] | GLP-1R-only comparator |
|---|---|---|---|
| Human GLP-1R | cAMP accumulation (EC₅₀) | 14 pM (full agonist, Emax 101%) | 9 pM |
| Human APJ (apelin receptor) | cAMP inhibition (EC₅₀) | 48 pM (full agonist) | inactive (>10 µM) |
| Human APJ | β-arrestin-2 recruitment (EC₅₀) | 220 pM (G-protein-biased ~5×) | inactive |
| Human GIP receptor | cAMP | inactive (>10 µM) | inactive |
| Human glucagon receptor | cAMP | inactive (>10 µM) | inactive |
| Species cross-reactivity (mouse/rat/monkey GLP-1R, APJ) | cAMP | within 3-fold of human | — |
Interpretation: GLPI-103 is a potent, full dual agonist of GLP-1R and APJ with no meaningful activity at the related GIP or glucagon receptors; the modest G-protein bias at APJ is consistent with the intended cardiometabolic (rather than purely β-arrestin) signalling.
Report PD-PRIM-01 — In-vivo efficacy in db/db and DIO mice (non-GLP)
Rationale: GLP is not required for primary efficacy pharmacology (ICH M3(R2)). Design: Male db/db mice (glycaemia) and diet-induced obese (DIO) mice (weight); randomised to vehicle, GLPI-103 low/mid/high (3/10/30 nmol/kg/day SC), or the GLP-1R-only comparator at matched exposure; 4-week dosing; OGTT, hyperinsulinaemic-euglycaemic clamp, body composition (NMR), and cardiometabolic biomarkers.
Endpoint (high dose) [MOCK] | Vehicle | GLP-1R-only | GLPI-103 |
|---|---|---|---|
| HbA1c change (%, 4 wk) | +0.3 | −1.1 | −1.8 |
| Body-weight change (%) | +2 | −12 | −18 |
| Cumulative food intake | reference | −22% | −28% |
| OGTT glucose AUC | reference | −34% | −47% |
| Clamp glucose-infusion rate (insulin sensitivity) | reference | +30% | +58% |
| Plasma NT-proBNP | reference | −10% | −34% |
| hsCRP | reference | −15% | −41% |
Mechanistic (APJ) substudy (echocardiography/telemetry): GLPI-103 produced a modest, apelin-consistent increase in cardiac fractional shortening and improved endothelial (flow-mediated) vasodilation not seen with the GLP-1R-only comparator, supporting APJ engagement in vivo. Conclusion: GLPI-103 delivers dual-mechanism efficacy exceeding GLP-1R agonism alone at matched exposure, with cardiometabolic benefit attributable to APJ — the translational basis for the clinical hypothesis.
4.2.1.2 Secondary Pharmacodynamics — Report PD-SEC-01 (non-GLP)
Broad off-target screen (~80 receptors, ion channels, transporters and enzymes; radioligand/functional): no inhibition or activation ≥50% at 10 µM except the intended targets. No relevant secondary pharmacology liability.
4.2.1.3 Safety Pharmacology — Report PD-SAFP-01 (GLP)
Core battery per ICH S7A/S7B, conducted under GLP (21 CFR 58 / OECD):
| System | Model | Result [MOCK] | Margin to clinical Cmax |
|---|---|---|---|
| hERG current | HEK293 patch clamp | IC₅₀ > 30 µM | >1,000× |
| Cardiovascular | telemetered cynomolgus monkey | no QTc prolongation; transient HR +10–15% (mechanism-related), resolving | >30× |
| Central nervous system | rat Irwin / functional observational battery | no adverse neurobehavioural effects | >50× |
| Respiratory | rat whole-body plethysmography | no effect on rate/tidal volume/minute volume | >50× |
Conclusion: No safety-pharmacology liability at therapeutic exposures; the transient heart-rate effect is the anticipated, monitorable class/mechanism effect (APJ/GLP-1).
4.2.1.4 Pharmacodynamic Drug Interactions — Report PD-DDI-01 (non-GLP)
Co-administration with metformin in db/db mice produced additive glucose lowering without adverse pharmacodynamic interaction, supporting the clinical add-on-to-metformin design. [MOCK]
Comments (0)
No comments yet. Be the first to say something!